Overview

Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

Status:
Terminated

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of the combination is limited.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Endothelin Receptor Antagonists
Sildenafil Citrate
Sitaxsentan